Condensed Consolidated Statements of Operations - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
Mar. 31, 2019 |
Mar. 31, 2018 |
|
| Research and development: | ||||
| Compensation and benefits | $ 869,354 | $ 1,569,840 | $ 1,798,173 | $ 4,553,650 |
| Consultants and outside costs | 134,609 | 157,759 | 307,771 | 521,918 |
| Material manufacturing costs | 8,912 | 219,192 | 554,433 | 872,883 |
| Facilities and other costs | 132,884 | 484,316 | 670,653 | 1,466,123 |
| Total research and development | 15,121,759 | 2,496,197 | 17,360,761 | 10,219,923 |
| General and administrative: | ||||
| Compensation and benefits | 1,101,938 | 1,797,385 | 3,733,486 | 5,265,306 |
| Professional fees | 199,117 | 181,258 | 406,658 | 618,251 |
| Investor relations | 194,276 | 64,347 | 252,236 | 257,923 |
| Other general and administrative | 419,562 | 414,297 | 1,006,489 | 1,060,168 |
| Total general and administrative | 1,914,893 | 2,457,287 | 5,398,869 | 7,201,648 |
| Operating loss | (17,036,652) | (4,953,484) | (22,759,630) | (17,421,571) |
| Interest expense: | ||||
| Beneficial conversion feature | (2,233,000) | 0 | (2,233,000) | 0 |
| Accretion of debt discount | (472,071) | 0 | (2,053,234) | 0 |
| At contractual rate | (42,840) | (53,363) | (660,190) | (53,510) |
| Derivative gains | 0 | 7,487 | 73,904 | 7,985 |
| Rent income | 0 | 31,406 | 153,071 | 95,082 |
| Interest income | 11,758 | 116 | 11,821 | 977 |
| Gain on lease termination | 0 | 0 | 167,788 | 0 |
| Total non-operating income (expense) | (2,736,153) | (14,354) | (4,539,840) | 50,534 |
| Net loss | (19,772,805) | (4,967,838) | (27,299,470) | (17,371,037) |
| Net loss attributable to common stockholders | $ (22,045,805) | $ (4,967,838) | $ (29,572,470) | $ (17,371,037) |
| Net loss per common share - basic and diluted | $ (0.36) | $ (0.09) | $ (0.48) | $ (0.32) |
| Weighted average number of common shares outstanding - basic and diluted | 61,866,319 | 54,073,309 | 62,053,126 | 53,573,410 |
| Clinical trial costs | ||||
| Research and development: | ||||
| Cost of Goods and Services Sold | $ 0 | $ 65,090 | $ 3,731 | $ 1,626,844 |
| License costs | ||||
| Research and development: | ||||
| Cost of Goods and Services Sold | $ 13,976,000 | $ 0 | $ 14,026,000 | $ 1,178,505 |
| X | ||||||||||
- Definition Amount of compensation and benefits for general and administrative during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount of compensation and benefits for research and development during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount of Consultants and outside costs during the reporting period. No definition available.
|
| X | ||||||||||
- Definition Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date. No definition available.
|
| X | ||||||||||
- Definition Amount of Facilities and other costs during the reporting period. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Investor relations for the during period. No definition available.
|
| X | ||||||||||
- Definition Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred in the production of goods for sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|